Effects of diabetes on cardiovascular drug metabolism: Emerging clinical implications

Diabetes Care

Volumn 22, Issue 6, 1999, Pages 982-988

  Preston, Richard A ^a   Epstein, Murray ^a  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ALPHA GLUCOSIDASE INHIBITOR; AMPICILLIN; ANTIHYPERTENSIVE AGENT; CALCIUM ANTAGONIST; CARDIOVASCULAR AGENT; CIPROFLOXACIN; CYCLOSPORIN A; CYTOCHROME P450 ISOENZYME; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ETHINYLESTRADIOL; FELODIPINE; GLIPIZIDE; GLYCOGEN; LORAZEPAM; MEVINOLIN; MIDAZOLAM; NIFEDIPINE; NISOLDIPINE; PARACETAMOL; SAQUINAVIR; TERFENADINE; THEOPHYLLINE; VERAPAMIL; VOGLIBOSE;

AREA UNDER THE CURVE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG FORMULATION; DRUG METABOLISM; DRUG TRANSFORMATION; FATTY LIVER; FRUIT JUICE; GASTROINTESTINAL ABSORPTION; HUMAN; HYPERTENSION; ORAL DRUG ADMINISTRATION; PHARMACODYNAMICS; PHARMACOKINETICS; REVIEW; STOMACH EMPTYING; URINARY EXCRETION;

ANIMALS; BIOTRANSFORMATION; CARDIOVASCULAR AGENTS; DIABETES MELLITUS; DIABETIC NEPHROPATHIES; HUMANS; INTESTINAL ABSORPTION; KIDNEY; TISSUE DISTRIBUTION;

EID: 0032971213     PISSN: 01495992     EISSN: None     Source Type: Journal    
DOI: 10.2337/diacare.22.6.982     Document Type: Review

References (72)

1. Estacio RO, Jeffers BW, Hiatt WR, Biggerstaff SL, Gifford N, Schrier RW: The effects of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N Engl J Med 338:645-652, 1998
2. Tatti P, Pahor M, Byington RP, DiMauro P, Gaurisco R, Strollo G, Strollo F: Outcome results of the Fosinopril Versus Amlodipine Cardiovascular Events Randomized Trial (FACET) in patients with hypertension and NIDDM. Diabetes Care 21:597-602, 1998
3. Parving H-H: Calcium antagonists and cardiovascular risk in diabetes. Am J Cardiol 82 (Suppl 9B):1R-44R, 1998
4. Poultert NR: Calcium antagonists and the diabetic patient: a response to recent controversies. Am J Cardiol 82 (Suppl. 9B):40R-41R, 1998
5. Epstein M: A symposium: calcium antagonists and the diabetic patient: recent controversies and future perspectives. Am J Cardiol 82 (Suppl. 9B):1R-44R, 1998
6. Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure: The sixth report of the Joint National Committee on Detection, Evaluation and Treatment of High Blood Pressure (JNC VI). Arch Intern Med 157:2413-2444, 1997
7. Preston RA, Singer I, Epstein M. Renal parenchymal hypertension: current concepts of pathogenesis and management. Arch Intern Med 154:637-642, 1996
8. Striker GE, Klahr S: Clinical trials in the progression of renal failure. Adv Intern Med 42:555-593, 1997
9. Preston RA: Renoprotective effects of antihypertensive drugs. Am J Hypertens 12 (Suppl. 1):19S-32S, 1999
10. Jacobson HR, Striker GE: Report on a workshop to develop management recommendations for the prevention of progression in chronic disease. Am J Kidney Dis 25:103-106, 1995
11. Mackenzie HS, Brenner BM: Current strategies for retarding progression of renal disease. Am J Kidney Dis 31:161-170, 1998
12. Lewis EJ, Hunsicker LG, Bain RP, Rohde RD: The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. N Engl J Med 329:1456-1462, 1993
13. Laffel LMB, McGill J, Gans D: The beneficial effects of angiotensin-converting enzyme inhibition with captopril on diabetic nephropathy in normotensive IDDM patients with microalbuminuria. Am J Med 99:497-503, 1995
14. Ravid M, Savin H, Jutrin I, Rental T, Katz B, Lishner M: Long-term stabilizing effect of angiotensin-converting enzyme inhibition on plasma creatinine and on proteinuria in normotensive type II diabetic patients. Ann Intern Med 118:577-581, 1993
15. Ravid M, Lang R, Rachmani R, Lishner M: Long-term renoprotective effect of angiotensin-converting enzyme inhibition in non-insulin dependent diabetes mellitus: a 7-year follow-up study Arch Intern Med 156:286-289, 1996
16. Materson BJ: ACE inhibitors as a shield against diabetic nephropathy. Arch Intern Med 156:239-240, 1996
17. Parving HH, Tarnow L, Rossing P: Renal protection in diabetes: an emerging role for calcium antagonists. J Hypertens 14 (Suppl. 4): S21-S25, 1996
18. Epstein M, Cooper M: Diabetic nephropathy: focus on ACE inhibition and calcium channel blockade. In Calcium Antagonists and Clinical Medicine. Epstein M, Ed. Philadelphia, Hanley & Belfus, 1998, p. 243-271
19. Makrilakis K, Bakris GL: Calcium antagonists: are they all created equal in regard to slowing progression diabetic nephropathy? In Calcium Antagonists and Clinical Medicine. Epstein M, Ed. Philadelphia, Hanley & Belfus, 1998, p. 393-411
20. Rossing P, Tarnow L, Boelskifte S, Jensen BR, Nielsen FS, Parving HH: Differences between nisoldipine and lisinopril on glomerular filtration rates and albuminuria in hypertensive IDDM patients with diabetic nephropathy during the first year of treatment. Diabetes 46:481-487, 1997
21. Velussi M, Brocco E, Frigato F, Zolli M, Muollo B, Maioli M, Carraro A, Tonolo G, Fresu P, Cemigoi AM, Fioretto P, Nosadini R: Effects of cilazapril and amlodipine on kidney function in hypertensive NIDDM patients. Diabetes 45:216-222, 1996
22. Bakris GL, Copley JB, Vicknair N, Sadler R, Leurgans S: Calcium channel blockers versus other antihypertensive therapies on progression of NIDDM associated nephropathy. Kidney Int 50:1641-1650, 1996
23. Bakris GL, Weir MR, DeQuattro V, Rosendorff C, MacMahon G: Renal hemodynamic and antiproteinuric response to an ACE inhibitor, trandolopril, or calcium antagonist, verapamil, alone or in fixed-dose combination in patients with diabetic nephropathy: a randomized multicentered study (Abstract). J Am Soc Nephrol 7:1546, 1996
24. Chan JCN, Critchley JAJH, Tomlinson B, Chan TYK, Cockram CS: Antihypertensive and anti-albuminuric effects of losartan potassium and felodipine in Chinese elderly hypertensive patients with or without non-insulin-dependent diabetes mellitus. Am J Nephrol 17:72-80, 1997
25. Gwilt PR, Nahhas RR, Tracewell WG: The effects of diabetes mellitus on pharmacokinetics and pharmacodynamics in humans. Clin Pharmacokinet 20:477-490, 1991
26. Shargel L, Yu ABC: Physiologic factors related to drug absorption. In Applied Biopharmaceutics and Pharmacokinetics. 3rd ed. Shargel L, Yu ABC, Eds. Stamford, CT, Appleton and Lange, 1993, p. 111-134
27. Shargel L, Yu ABC: Pharmacokinetics of drug absorption. In Applied Biopharmaceutics and Pharmacokinetics. 3rd ed. Shargel L, Yu ABC, Eds. Stamford, CT, Appleton and Lange, 1993, p. 169-192
28. Shargel L, Yu ABC: Modified-release drug products and targeted drug delivery systems. In Applied Biopharmaceutics and Pharmacokinetics. 3rd ed. Shargel L, Yu ABC, Eds. Stamford, CT, Appleton and Lange, 1993, p. 225-264
29. Rowland M, Tozer TN: Absorption. In Clinical Pharmacokinetics. Rowland M, Tozer TN, Eds. Media, PA, Williams and Wilkins, 1995, p. 119-136
30. Rowland M, Tozer TN: Movement through membranes. In Clinical Pharmacokinetics. Rowland M, Tozer TN, Eds. Media, PA, Williams and Wilkins, 1995, p. 109-118
31. Bailey DG, Arnold JMO, Spence JD: Grapefruit juice and drugs: how significant is the interaction? Clin Pharmacokinet 26:91-98, 1994
32. Bailey DG, Arnold JMO, Strong HA: Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics. Clin Pharmacol Ther 54:589-594, 1993
33. Bailey DG, Spence JD, Munoz C, Arnold JMO: Interaction of citrus juices with felodipine and nifedipine. Lancet 337:268-269, 1991
34. Fuhr U, Harder S, Lopez-Rojas P, Muller-Peltzer H, Kern R, Staib AH: Increase of verapamil concentrations in steady state by coadministration of grapefruit juice (Abstract). Naunyn Schmicdebergs Arch Pharmacol 349:R134, 1994
35. Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL: Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. Clin Pharmacol Ther 59:383-388, 1996
36. Weber A, Jager R, Borner A, Klinger G, Vollanth R, Matthey K, Balogh A: Can grapefruit juice influence ethinylestradiol bioavailability? Contraception 53:41-47, 1996
37. Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PS, Krihenbuhl S: Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther 58:20-28, 1996
38. Kupferschmidt HH, Fattinger KE, Ha HR, Follath F, Krahenbuhl S: Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br J Clin Pharmacol 45:355-359, 1998
39. Kantola T, Kivisto KT, Neuvonen PJ: Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther 63:397-402, 1998
40. Ducharmc MP, Warbasse LH, Edwards DJ: Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmncol Ther 57:485-491, 1995
41. Lown KS, Bailey DG, Fontana RJ, Janardan SK, Adair C, Fortlage LA, Brown MB, Guo W, Watkins PB: Grapefruit juice increases felodipine oral availability in humans by decreasing intestinal CYP3A protein expression. J Clin Invest 99:2545-2553, 1997
42. Barkin JS, Robbins EG 2nd, Stein B: Diabetes and the GI system. In Diabetes Mellitus. 5th ed. Porte D Jr, Sherwin RS, Eds. Stamford, CT, Appleton & Lange, 1996, p.1183-1205
43. Weber JR, Ryan JC: Effect in the gut of systemic disease and other extraintestinal conditions. In Sleisenger and Fordtran's Gastrointestinal and Liver Disease. Feldman M, Scharschmidt BF, Sleisenger MH, Eds. Philadelphia, PA, W.B. Saunders, 1998, p. 411-438
44. Schwartz JG, Green GM, Guan D, McMahan CA, Phillips WT: Rapid gastric emptying of a solid pancake meal in type II diabetic patients. Diabetes Care 19:468-471, 1996
45. Lipp RW, Schnedl J, Hammer HF, Kotanko P, Leb G, Krejs: Evidence of accelerated gastric emptying in longstanding diabetic patients after ingestion of a semisolid meal. J Nutl Med 38:814-818, 1997
46. Groger G, Layer P: Exocrine pancreatic function in diabetes mellitus. Eur J Gastroenterol Hepatol 7:740-746, 1995
47. Kawagishi T, Nishizawa Y, Taniwaki H, Tanaka S, Okuno Y, lnaba M, Ishimura E, Emoto M, Morii H: Relationship between gastric emptying and an alpha-glucosidase inhibitor effect on postprandial hyperglycemia in NIDDM patients. Diabetes Care 20:1529-1532, 1997
48. Della-Coletta AA, Eller MG: The bioavailability of tolazamide in diabetic patients and healthy subjects (Abstract). Pharm Res 5:174, 1988
49. Adithan C, Danda D, Swaminathan RP, Indhiresan J, Shashindran CH, Chandrasekar S: Effect of type 1 diabetes mellitus on theophylline elimination. Med Sci Res 16:427-428, 1988
50. von Nicolai H, Brickl R, Eschey H, Greischel A, Heinzel G, Konig E, Limmer J, Rupprecht E: Duration of action and pharmacokinetics of the oral antidiabetic drug gliquidone in patients with non-insulin-dependent (type 2) diabetes mellitus. Arzneimittelforschung 47:247-252, 1997
51. Jaber LA, Ducharme MP, Halapy H: The effects of obesity on the pharmacokinetics and pharmacodynamics of glipizide in patients with non-insulin-dependent diabetes mellitus. Ther Drug Monit 18:6-13, 1996
52. Marangos MN, Skoutelis AT, Nightingale CH, Zhu Z, Psyrogiannis AG, Nicolau DP, Bassaris HP, Quintiliani R: Absorption of ciprofloxacin in patients with diabetic gastroparesis. Antimicrob Agents Chemother 39:2161-2163, 1995
53. Fraze E, Donner CC, Swislocki AL, Chiou YA, Chen YD, Reaven GM: Ambient plasma free fatty acid concentrations in noninsulin-dependent diabetes mellitus: evidence for insulin resistance. J Clin Endocrinol Metab 61:807-811, 1985
54. Gatti G, Crema F, Attardo-Parrinello G, Fratino P, Aguzzi F, Perucca E: Serum protein binding of phenytoin and valproic acid in insulin-dependent diabetes mellitus. Ther Drug Monit 9:389-391, 1987
55. McNamara PJ, Blouin RA, Brazzell RK: The protein binding of phenytoin, propranolol, diazepam and ALO1 576 (an aldose reductase inhibitor) in human and rat diabetic serum. Pharm Res 5:261-265, 1988
56. Worner W, Preissner A, Kratzer W, Keita Y, Rietbrock N: Drug binding kinetics in patients with diabetes mellitus. Int J Clin Pharmacol Ther Toxicol 30:489-490, 1992
57. Watkins JB 3rd, Sanders RA: Diabetes mellitus-induced alterations of hepatobiliary function. Pharmacol Rev 47:1-23, 1995
58. Bechtel YC, Joanne C, Grandmottet M, Bechtel PR: The influence of insulin-dependent diabetes on the metabolism of caffeine and the expression of the debrisoquin oxidation phenotype. Clin Pharmacol Ther 44:408-417, 1988
59. Herman RJ, Chaudhary A, Szakacs CB, Woo D, Lane R, Boctor MA: Disposition of lorazepam in diabetes: differences between patients treated with beef/pork and human insulins. EurJ Clin Pharmacol 48:253-258, 1995
60. Adithan C, Danda D, Swaminathan RP, Indhiresan J, Shashindran CH, Bapna JS, Chandrasekar S: Effect of diabetes on salivary paracetamol elimination. Clin Exp Pharmacol Physiol 15:465-471, 1988
61. Adithan C, Danda D, Swaminathan RP, Indhiresan J, Shashindran CH, Chandrasekar S: Effect of type I diabetes mellitus on theophylline elimination. Med Sci Res 16:427-428, 1988
62. Adithan C, Sriram G, Swaminathan RP, Krishnan M, Bapna JS, Chandrasekar S: Effect of type II diabetes mellitus on theophylline elimination. Int J Clin Pharmacol Ther Toxicol 27:258-260, 1989
63. Parving H-H, Osterby R, Anderson PW, Hsueh WA: Diabetic nephropathy. In The Kidney. 5th ed. Brenner BM, Ed. Philadelphia, PA, W.B. Saunders, 1996, p. 1864-1892
64. Defronzo RA: Diabetic nephropathy. In Diabetes Mellitus. 5th ed. Porte D Jr, Sherwin RS, Eds. Stamford, CT, Appleton & Lange, 1996, p. 971-1008
65. Trevisan R, Viberti G: Pathophysiology of diabetic nephropathy. In Diabetes Mellitus: A Fundamental and Clinical Text. LeRoith D, Taylor SI, Olefsky JM, Eds. Philadelphia, PA, Lippincott-Raven, p. 727-736, 1996
66. Haria M, Wagstaff AJ: Amlodipine. Drugs 50:560-586, 1995
67. Plosker GL, Faulds D: Nisoldipine coat-core. Drugs 52:232-253, 1996
68. Schall R, Müller FO, Groenwoud G: Single-dose and steady-state pharmacokinetic and pharmacodynamic profiles of nisoldipine coat-core tablets in healthy young, healthy elderly, and elderly hypertensive volunteers. Drug Invest 3:21-30, 1994
69. Zannad F: Clinical pharmacology of nisoldipine coat-core. Am J Cardiol 75:41E-45E, 1995
70. Lasseter KC, Müller FO, Garrett BN: Pharmacokinetics, pharmacodynamics, and clinical utility of nisoldipine coat-core in the treatment of hypertension. Cardiovosc Rev Rep 17:28-46, 1996
71. Chandler MHH, Clifton GD, Lettieri JT: Multiple dose pharmacokinetics of four different doses of nisoldipine in hypertensive patients. J Clin Pharmacol 32:571-575, 1992
72. Schaefer HG, Heinig R, Ahr G: Pharmacokinetic-pharmacodynamic modelling as a tool to evaluate the clinical relevance of a drug-food interaction for a nisoldipine controlled-release dosage form. Eur J Clin Pharmacol 51:473-480, 1997